Genomenon highlighted 2024 advancements, collaborations, solutions, and scientific achievements related to making genomic information actionable and curating the human genome.
Fabry disease is a rare, X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene. Loss of alpha-galactosidase A activity leads to globotriaosylceramide accumulation in lysosomes and cellular dysfunction.
The page discusses how genomic intelligence can inform cancer clinical trial design, regulatory submissions, and companion diagnostics as drug candidates enter clinical evaluation.
Genomenon is a genomic intelligence company that organizes genomic knowledge for clinicians diagnosing and treating rare diseases and cancer, and for precision medicine companies developing targeted therapies.
Actionable Genomic Evidence at the Gene & Variant Level Aligned with ACMG/AMP. Supporting Patient Diagnosis & Precision Medicine for Rare Disease & Cancer.
